New to 2018: The Role of Artificial Intelligence in Drug Discovery

SMi Reports: SMi’s 2nd annual Drug Discovery conference will discuss the role of artificial intelligence in drug discovery

LONDON, UNITED KINGDOM, October 30, 2017 /EINPresswire.com/ -- ‘The biopharmaceutical industry are looking toward AI to speed up drug discovery, cut R&D costs, decrease failure rates in drug trials and eventually create better medicines’ Source: Forbes

Against this backdrop, SMi’s 2nd annual Drug Discovery conference will discuss the role of artificial intelligence (AI) in the Drug Discovery process. Leading experts from ETH Zurich, Exscientia, Benovolent AI and Astrazeneca will be speaking on this subject. These highly acclaimed professionals will be discussing Artificially Intelligent Drug Design, Transforming Small Molecule Drug Discovery Using Artificial Intelligence, Disrupting Drug Discovery with AI and Machine Learning for Smarter Drug Discovery.

The event will also cover an array of topics which include Advancements in Small Molecule Therapeutics, Discovering New Experimental Technologies and Exploring Alternate Approaches & Modalities.

Alongside the two-day conference, there will be two pre-conference workshops taking place on Tuesday 20th March 2018. The morning session will be led by Nicolas Clare, Technical Project Leader at Axol Bioscience. He will discuss Induced Pluripotent Stem Cell Derived Models and their use in Drug Discovery. The workshop is aimed at those who would like to understand the revolutionary biological technique of creating induced pluripotent stem cells (Ipsc) from any source material, differentiating them into different cell lineages and their use in drug discovery, either as healthy controls or disease models.

The afternoon workshop will be led by Emanuela Cuomo, Associate Principal Scientist at AstraZeneca who will provide an overview of CRISPR/Cas technologies and how they are applied to drug development. Specific examples will illustrate how genome editing is used in AstraZeneca pipeline to improve target identification and validation; also how it can be used to predict drug resistance and direct drug optimisation.

For more details about the conference and registration information, visit www.drug-discovery.co.uk/EINPR

Drug Discovery
21st – 22nd March 2018
Copthorne Tara Hotel, London, UK
www.drug-discovery.co.uk/EINPR

https://www.forbes.com/sites/forbestechcouncil/2017/08/03/artificial-intelligence-in-drug-discovery-a-bubble-or-a-revolutionary-transformation/#2540e4a84494

---end ---

Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Kieran Ronaldson at kronaldson@smi-online.co.uk. For media queries please contact Natasha Boumediene at nboumediene@smi-online.co.uk.

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Natasha Boumediene
SMi Group
+44 (0) 207 827 6020
email us here

Powered by EIN Presswire